185 related articles for article (PubMed ID: 36403589)
1. Quality-of-life outcomes in older patients with early-stage rectal cancer receiving organ-preserving treatment with hypofractionated short-course radiotherapy followed by transanal endoscopic microsurgery (TREC): non-randomised registry of patients unsuitable for total mesorectal excision.
Gilbert A; Homer V; Brock K; Korsgen S; Geh I; Hill J; Gill T; Hainsworth P; Tutton M; Khan J; Robinson J; Steward M; Cunningham C; Kaur M; Magill L; Russell A; Quirke P; West NP; Sebag-Montefiore D; Bach SP;
Lancet Healthy Longev; 2022 Dec; 3(12):e825-e838. PubMed ID: 36403589
[TBL] [Abstract][Full Text] [Related]
2. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.
Bach SP; Gilbert A; Brock K; Korsgen S; Geh I; Hill J; Gill T; Hainsworth P; Tutton MG; Khan J; Robinson J; Steward M; Cunningham C; Levy B; Beveridge A; Handley K; Kaur M; Marchevsky N; Magill L; Russell A; Quirke P; West NP; Sebag-Montefiore D;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):92-105. PubMed ID: 33308452
[TBL] [Abstract][Full Text] [Related]
3. Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC)? Protocol for the international, multicentre, rolling phase II/III partially randomized patient preference trial evaluating long-course concurrent chemoradiotherapy versus short-course radiotherapy organ preservation approaches.
Bach SP;
Colorectal Dis; 2022 May; 24(5):639-651. PubMed ID: 35114057
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
5. STAR-TREC: An International Three-arm Multicentre, Partially Randomised Controlled Trial Incorporating an External Pilot.
Bach SP
Clin Oncol (R Coll Radiol); 2023 Feb; 35(2):e107-e109. PubMed ID: 36577551
[TBL] [Abstract][Full Text] [Related]
6. Results of neoadjuvant short-course radiation therapy followed by transanal endoscopic microsurgery for t1-t2 n0 extraperitoneal rectal cancer.
Arezzo A; Arolfo S; Allaix ME; Munoz F; Cassoni P; Monagheddu C; Ricardi U; Ciccone G; Morino M
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):299-306. PubMed ID: 25772184
[TBL] [Abstract][Full Text] [Related]
7. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
8. Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study.
Stijns RCH; de Graaf EJR; Punt CJA; Nagtegaal ID; Nuyttens JJME; van Meerten E; Tanis PJ; de Hingh IHJT; van der Schelling GP; Acherman Y; Leijtens JWA; Bremers AJA; Beets GL; Hoff C; Verhoef C; Marijnen CAM; de Wilt JHW;
JAMA Surg; 2019 Jan; 154(1):47-54. PubMed ID: 30304338
[TBL] [Abstract][Full Text] [Related]
9. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
10. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).
Serra-Aracil X; Pericay C; Badia-Closa J; Golda T; Biondo S; Hernández P; Targarona E; Borda-Arrizabalaga N; Reina A; Delgado S; Vallribera F; Caro A; Gallego-Plazas J; Pascual M; Álvarez-Laso C; Guadalajara-Labajo HG; Mora-Lopez L
Ann Oncol; 2023 Jan; 34(1):78-90. PubMed ID: 36220461
[TBL] [Abstract][Full Text] [Related]
11. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
Velikova G; Williams LJ; Willis S; Dixon JM; Loncaster J; Hatton M; Clarke J; Kunkler IH; Russell NS;
Lancet Oncol; 2018 Nov; 19(11):1516-1529. PubMed ID: 30337220
[TBL] [Abstract][Full Text] [Related]
12. Can we
Rombouts AJM; Al-Najami I; Abbott NL; Appelt A; Baatrup G; Bach S; Bhangu A; Garm Spindler KL; Gray R; Handley K; Kaur M; Kerkhof E; Kronborg CJ; Magill L; Marijnen CAM; Nagtegaal ID; Nyvang L; Peters FP; Pfeiffer P; Punt C; Quirke P; Sebag-Montefiore D; Teo M; West N; de Wilt JHW;
BMJ Open; 2017 Dec; 7(12):e019474. PubMed ID: 29288190
[TBL] [Abstract][Full Text] [Related]
13. Quality of life after transanal endoscopic microsurgery and total mesorectal excision in early rectal cancer.
Doornebosch PG; Tollenaar RA; Gosselink MP; Stassen LP; Dijkhuis CM; Schouten WR; van de Velde CJ; de Graaf EJ
Colorectal Dis; 2007 Jul; 9(6):553-8. PubMed ID: 17573752
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in non-early rectal cancer treated by neoadjuvant radio-chemotherapy and endoluminal loco-regional resection (ELRR) by transanal endoscopic microsurgery (TEM) versus laparoscopic total mesorectal excision.
D'Ambrosio G; Paganini AM; Balla A; Quaresima S; Ursi P; Bruzzone P; Picchetto A; Mattei FI; Lezoche E
Surg Endosc; 2016 Feb; 30(2):504-511. PubMed ID: 26045097
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Kitchener HC; Nijman HW; Kruitwagen RF; Nout RA; Verhoeven-Adema KW; Smit VT; Putter H; Creutzberg CL;
Lancet Oncol; 2016 Aug; 17(8):1114-1126. PubMed ID: 27397040
[TBL] [Abstract][Full Text] [Related]
18. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
Rullier E; Rouanet P; Tuech JJ; Valverde A; Lelong B; Rivoire M; Faucheron JL; Jafari M; Portier G; Meunier B; Sileznieff I; Prudhomme M; Marchal F; Pocard M; Pezet D; Rullier A; Vendrely V; Denost Q; Asselineau J; Doussau A
Lancet; 2017 Jul; 390(10093):469-479. PubMed ID: 28601342
[TBL] [Abstract][Full Text] [Related]
19. Long-term Quality of Life and Functional Outcome of Patients With Rectal Cancer Following a Watch-and-Wait Approach.
Custers PA; van der Sande ME; Grotenhuis BA; Peters FP; van Kuijk SMJ; Beets GL; Breukink SO;
JAMA Surg; 2023 May; 158(5):e230146. PubMed ID: 36988922
[TBL] [Abstract][Full Text] [Related]
20. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
